PITAR, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA
eLife · 20.09.2024 · 12
DOI: 10.7554/elife.88256 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 20.09.2024. Verfasst von Samarjit Jana und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Cell Biology, Indian Institute of Science Bangalore, Bangalore, India. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, RNA, Long Noncoding, DNA Damage, Tripartite Motif-Containing Protein 28. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Human Resource Development, Department of Science and Technology, Ministry of Science and Technology, India, Swedish Cancer Research Foundation.
Abstract (Originalsprache)
In tumors with WT p53, alternate mechanisms of p53 inactivation are reported. Here, we have identified a long noncoding RNA, PITAR ( p 53 I nactivating T RIM28 A ssociated R NA), as an inhibitor of p53. PITAR is an oncogenic Cancer/testis lncRNA and is highly expressed in glioblastoma (GBM) and glioma stem-like cells (GSC). We establish that TRIM28 mRNA, which encodes a p53-specific E3 ubiquitin ligase, is a direct target of PITAR. PITAR interaction with TRIM28 RNA stabilized TRIM28 mRNA, which resulted in increased TRIM28 protein levels and reduced p53 steady-state levels due to enhanced p53 ubiquitination. DNA damage activated PITAR , in addition to p53, in a p53-independent manner, thus creating an incoherent feedforward loop to inhibit the DNA damage response by p53. While PITAR silencing inhibited the growth of WT p53 containing GSCs in vitro and reduced glioma tumor growth in vivo, its overexpression enhanced the tumor growth in a TRIM28 -dependent manner and promoted resistance to Temozolomide. Thus, we establish an alternate way of p53 inactivation by PITAR , which maintains low p53 levels in normal cells and attenuates the DNA damage response by p53. Finally, we propose PITAR as a potential GBM therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Cell Biology, Indian Institute of Science Bangalore, Bangalore, India.
- Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
- Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India.
ORCID-Profile: Samarjit Jana, Abhishek Chowdhury, Kumaravel Somasundaram
Förderung
- Ministry of Human Resource Development
- Department of Science and Technology, Ministry of Science and Technology, India
- Swedish Cancer Research Foundation
- Swedish Research Council
- Barncancerfonden
- IngaBritt och Arne Lundbergs Forskningsstiftelse
- LUA/ALF and the VAJRA Faculty Scheme
- Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Jana, S., Mondal, M., Mahale, S., Gupta, B., Prasasvi, K. R., Kandasami, L., Jha, N., Chowdhury, A., Santosh, V., Kanduri, C., & Somasundaram, K. (2024). PITAR, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA. eLife, 12. https://doi.org/10.7554/elife.88256
Vancouver
Jana S, Mondal M, Mahale S, Gupta B, Prasasvi KR, Kandasami L, et al. PITAR, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA. eLife. 2024;12. doi:10.7554/elife.88256
BibTeX
@article{Jana2024,
author = {Jana, Samarjit and Mondal, Mainak and Mahale, Sagar and Gupta, Bhavana and Prasasvi, Kaval Reddy and Kandasami, Lekha and Jha, Neha and Chowdhury, Abhishek and Santosh, Vani and Kanduri, Chandrasekhar and Somasundaram, Kumaravel},
title = {PITAR, a DNA damage-inducible cancer/testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA},
journal = {eLife},
year = {2024},
volume = {12},
doi = {10.7554/elife.88256}
}
EUVIMED